S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Avanos Medical (AVNS) Stock Forecast, Price & News

+0.78 (+2.79%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
190,878 shs
Average Volume
336,402 shs
Market Capitalization
$1.36 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AVNS News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

Avanos Medical logo

About Avanos Medical

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.


See More Headlines

Industry, Sector and Symbol

Surgical appliances & supplies
Year Founded

Sales & Book Value

Annual Sales
$744.60 million
Cash Flow
$2.00 per share
Book Value
$26.55 per share


Net Income
$5.20 million
Pretax Margin




Free Float
Market Cap
$1.36 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.05 out of 5 stars

Medical Sector

522nd out of 1,424 stocks

Surgical Appliances & Supplies Industry

15th out of 30 stocks

Analyst Opinion: 3.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Avanos Medical (NYSE:AVNS) Frequently Asked Questions

Is Avanos Medical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Avanos Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View analyst ratings for Avanos Medical
or view top-rated stocks.

When is Avanos Medical's next earnings date?

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Avanos Medical

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) announced its quarterly earnings results on Wednesday, May, 4th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. The firm earned $197.40 million during the quarter, compared to analyst estimates of $197.80 million. Avanos Medical had a net margin of 2.44% and a trailing twelve-month return on equity of 4.49%. The firm's revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.23 EPS.
View Avanos Medical's earnings history

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical issued an update on its FY 2022 earnings guidance on Wednesday, May, 11th. The company provided earnings per share (EPS) guidance of $1.55-$1.75 for the period, compared to the consensus earnings per share estimate of $1.64. The company issued revenue guidance of $830.00 million-$850.00 million, compared to the consensus revenue estimate of $842.09 million.

What price target have analysts set for AVNS?

3 Wall Street analysts have issued 1 year price targets for Avanos Medical's stock. Their forecasts range from $36.00 to $45.00. On average, they expect Avanos Medical's share price to reach $40.67 in the next year. This suggests a possible upside of 41.7% from the stock's current price.
View analysts' price targets for Avanos Medical
or view top-rated stocks among Wall Street analysts.

Who are Avanos Medical's key executives?
Avanos Medical's management team includes the following people:
  • Mr. Joseph F. Woody, CEO & Director (Age 56, Pay $1.68M)
  • Mr. Michael C. Greiner, Sr. VP, CFO & Principal Accounting Officer (Age 49, Pay $711.12k)
  • Mr. David Edward Ball, Sr. VP of Global Supply Chain & Procurement (Age 63, Pay $553.42k)
  • Mr. William David Haydon, Sr. VP & GM of Pain Management (Age 55, Pay $597.29k)
  • Mr. Kerr W. Holbrook, Sr. VP & GM of Chronic Care (Age 55, Pay $611.54k)
  • Mr. David Crawford, VP of FP&A and Investor Relations and Treasurer
  • Ms. Michelle Scharfenberg, Sr. VP and Chief Ethics & Compliance Officer
  • Ms. Mojirade James, Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. Scott Galovan, VP of Strategy & Corp. Devel.
  • Mr. Arjun Ranjan Sarker, Sr. VP of International (Age 56)
What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical CEO Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among Avanos Medical's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), (HON), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.09%), Vanguard Group Inc. (11.27%), RGM Capital LLC (6.25%), Paradice Investment Management LLC (5.20%), Dimensional Fund Advisors LP (5.00%) and State Street Corp (4.27%).
View institutional ownership trends for Avanos Medical

Which institutional investors are selling Avanos Medical stock?

AVNS stock was sold by a variety of institutional investors in the last quarter, including Paradice Investment Management LLC, Wellington Management Group LLP, Principal Financial Group Inc., BNP Paribas Arbitrage SA, Exchange Traded Concepts LLC, Neuberger Berman Group LLC, APG Asset Management N.V., and First Trust Advisors LP.
View insider buying and selling activity for Avanos Medical
or view top insider-selling stocks.

Which institutional investors are buying Avanos Medical stock?

AVNS stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Arrowstreet Capital Limited Partnership, Hillsdale Investment Management Inc., Charles Schwab Investment Management Inc., Vanguard Group Inc., ClariVest Asset Management LLC, and Lazard Asset Management LLC.
View insider buying and selling activity for Avanos Medical
or or view top insider-buying stocks.

How do I buy shares of Avanos Medical?

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $28.70.

How much money does Avanos Medical make?

Avanos Medical has a market capitalization of $1.36 billion and generates $744.60 million in revenue each year. The company earns $5.20 million in net income (profit) each year or $0.379990 on an earnings per share basis.

How many employees does Avanos Medical have?

Avanos Medical employs 4,555 workers across the globe.

What is Avanos Medical's official website?

The official website for Avanos Medical is avanos.com.

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at (844) 428-2667 or via email at [email protected].

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.